Key result
Pretreatment with KGA-2727 improved left ventricular fractional shortening and inhibited markers of ventricular remodeling and fibrosis in mice with myocardial infarction.
Why the study?
SGLT1 is associated with human ischemic cardiomyopathy, but whether SGLT1 blockade is effective against ischemic cardiomyopathy remains uncertain.
Pretreatment with the selective SGLT1 inhibitor KGA-2727 protects against left ventricular remodeling and heart failure following myocardial infarction in a mouse model.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for SGLT1 inhibition post-MI; clinical trials needed before any human application.
Recent studies demonstrated that sodium-glucose co-transporter 1 (SGLT1) is associated with human ischemic cardiomyopathy. However, whether SGLT1 blockade is effective against ischemic cardiomyopathy is still uncertain. We examined the effects of KGA-2727, a selective SGLT1 inhibitor, on myocardial infarction (MI)-induced ischemic cardiomyopathy. To create MI, left anterior descending coronary artery (LAD) ligation with or without KGA-2727 administration was performed in C57BL/6J mice. Four weeks after the operation, all mice were investigated. Left ventricular fractional shortening (LVFS) was reduced and KGA-2727 significantly improved it in LAD-ligated MI mice. The cardiomyocyte diameter, and ANP, BNP, β-MHC, and IL-18 gene expressions significantly increased in LAD-ligated mouse left ventricles compared with those of sham-operated mouse left ventricles, and KGA-2727 inhibited increases in them. Myocardial fibrosis and upregulation of CTGF and MMP-3 gene expressions in the left ventricle were increased in LAD-ligated mice compared with sham-operated mice, and KGA-2727 decreased them in the LAD-ligated left ventricles. SGLT1 protein expression level was significantly higher in LAD-ligated compared with sham-operated mouse ventricles regardless of KGA-2727 treatment. These results suggest that KGA-2727 pretreatment protects against MI-induced left ventricular remodeling through SGLT1 blockade and that it may become a new pharmacological therapy for ischemia-induced cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Sawa et al. (2019) studied Myocardial infarction-induced ischemic cardiomyopathy. KGA-2727 vs. No KGA-2727 administration / sham operation was evaluated on Left ventricular fractional shortening (LVFS) and markers of ventricular remodeling. Pretreatment with KGA-2727 improved left ventricular fractional shortening and inhibited markers of ventricular remodeling and fibrosis in mice with myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: